Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Yvanka Gilliam, Diaceutics VP of Operations, APAC, said: "I'm delighted to join Diaceutics, a company that I have long admired for their unwavering commitment to drive better testing and better treatment for patients. I look forward to broadening Diaceutics' influence in the APAC region and working alongside a team of driven and talented individuals. I'm particularly excited to come on board as the company's DXRX - The Diagnostic Network® platform continues to gain traction within the industry, as we help get every patient the treatment they deserve."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
PARSIPPANY, N.J. -- Businesswire -- Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC).
In her new role, Yvanka will be responsible for managing business development and operations within the APAC region with a core focus on establishing key collaborations and strategic partnerships to drive growth and revenue. Her role will also include identifying innovative and creative services and solutions to help leverage the company’s platform, DXRX, and increase the offering.
Yvanka has a strong track record managing the delivery of real-world insights for evaluation by regulators, payers and clinicians. Prior to joining Diaceutics, Yvanka worked with Kantar Health as a Senior Client Partner, Real World Evidence, where she developed and implemented global business planning strategies and conducted high-quality research. In recent years, Yvanka has also worked with IQVIA Asia Pacific in the Real World Insights Division and as a Senior Medical Science Liaison at AstraZeneca Pharmaceutical Corporation.
Yvanka holds a doctorate degree in Pharmacy from The University of Michigan College of Pharmacy in Ann Arbor, a bachelor’s degree in Biology and Chemistry from Grambling University in Louisiana and an MBA in International Business from Rutgers University Singapore. Yvanka’s work has been published in the Annals of Oncology and the Journal of Clinical Oncology - an American Society of Clinical Oncology (ASCO) Journal.
Peter Keeling, Chief Executive Officer of Diaceutics, said: “Yvanka’s appointment will strengthen Diaceutics’ credentials as the market leader in the development and commercialization of precision medicine diagnostics. As her 20-plus year career in pharma has been focused primarily on the Research and Development of innovative oncology compounds, Yvanka is firmly aligned with Diaceutics’ goal to bridge the gap between diagnostics and therapeutic decision-making in order to improve testing outcomes for patients and enable better access to the right drug at the right time.”
Yvanka Gilliam, Diaceutics VP of Operations, APAC, said: “I’m delighted to join Diaceutics, a company that I have long admired for their unwavering commitment to drive better testing and better treatment for patients. I look forward to broadening Diaceutics’ influence in the APAC region and working alongside a team of driven and talented individuals. I’m particularly excited to come on board as the company’s DXRX - The Diagnostic Network® platform continues to gain traction within the industry, as we help get every patient the treatment they deserve.”
-ENDS-
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first diagnostic network for precision medicine. Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005504/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Diaceutics PLC
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자 ‘인·식바꿈’ 프로모션 실시 - 뉴스와이어
- 에너지 볼트-스키드모어, 오윙스 앤 메릴, 에너지 저장을 건물 설계에 통합하는 글로벌 중력 에
- 삼성전자 ‘비스포크 스팀’ 신제품 출시… 로봇청소기 라인업 확대 - 뉴스와이어
- 아큐타 바이오테크놀로지, ASCO 2024에서 ER+/HER2- 유방암 환자를 대상으로 한 AC699 단독요법의 제1상
- 서틱, 온체인 혁신의 미래 형성하기 위한 ‘CertiK Ventures’ 출시 - 뉴스와이어
- 용산구시설관리공단, 2024년 국가재난관리 유공 ‘국무총리표창’ 수상 - 뉴스와이어
- UAE, 산업 오프테이크에 62억6000만달러 추가 투자 약정 확보 - 뉴스와이어
- 한국환경보전원, ESG 경영 실천 위해 공공기관 협업 생태계 교란 식물 제거 활동 추진 - 뉴스와이
- Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024 - 뉴
- 국제아로마테라피임상연구센터, 북광주농협 여성대학에서 행복한 중년기를 위한 ‘힐링 아로마